World's first CRISPR gene-editing treatment just received regulatory approval
Casgevy is designed to address two debilitating blood disorders: sickle cell disease (SCD) and transfusion-dependent beta-thalassemia.
The Brighter Side of News features good news, compassionate news and inspirational news from around the world